Segment Reporting

9 Months Ended

May 31, 2016

Segment Reporting [Abstract]

Segment Reporting

Note 18. Segment Reporting

The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

· The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.

· The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.

· The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen reported on a two-month lag. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.

The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations and Unallocated Items” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.

The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit.

The Company’s Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which the Company acquired the 55% of Alliance Boots that it did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only five months of results (January to May 2015) have been reported for these segments for the nine months ended May 31, 2015.

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Retail Pharmacy
	USA		International		Pharmaceutical Wholesale		Eliminations and Unallocated  Items			Consolidated
Three Months Ended May 31, 2016
Sales to external customers	$	21,185	$	3,132	$	5,181	$	-		$	29,498
Intersegment sales		-		62		567		(629	)		-
Total Sales	$	21,185	$	3,194	$	5,748	$	(629	)	$	29,498
Adjusted Operating Income	$	1,382	$	258	$	179	$	(5	)	$	1,814

Three Months Ended May 31, 2015
Sales to external customers	$	20,425	$	3,231	$	5,139	$	-		$	28,795
Intersegment sales		-		37		569		(606	)		-
Total Sales	$	20,425	$	3,268	$	5,708	$	(606	)	$	28,795
Adjusted Operating Income	$	1,328	$	249	$	171	$	1		$	1,749

	Retail Pharmacy
	USA		International		Pharmaceutical  Wholesale		Eliminations  and Unallocated Items			Consolidated
Nine Months Ended May 31, 2016
Sales to external customers	$	63,055	$	10,218	$	15,442	$	-		$	88,715
Intersegment sales		-		196		1,729		(1,925	)		-
Total Sales	$	63,055	$	10,414	$	17,171	$	(1,925	)	$	88,715
Adjusted Operating Income	$	4,257	$	908	$	500	$	(12	)	$	5,653

Nine Months Ended May 31, 2015
Sales to external customers	$	61,027	$	5,248	$	8,647	$	-		$	74,922
Intersegment sales		-		67		926		(993	)		-
Total Sales	$	61,027	$	5,315	$	9,573	$	(993	)	$	74,922
Adjusted Operating Income	$	4,044	$	374	$	292	$	(3	)	$	4,707

The following table reconciles adjusted operating income to operating income (in millions):

	Retail Pharmacy
	USA		International		Pharmaceutical Wholesale		Eliminations  and Unallocated Items			Consolidated
Three Months Ended May 31, 2016
Operating Income										$	1,533
Acquisition-related amortization											100
LIFO provision											93
Cost transformation											73
Acquisition-related costs											15
Adjusted Operating Income	$	1,382	$	258	$	179	$	(5	)	$	1,814

Three Months Ended May 31, 2015
Operating Income									$	1,401
Acquisition-related amortization										96
LIFO provision										69
Cost transformation										160
Acquisition-related costs										4
Store closures and other optimization costs										7
Loss on sale of business										12
Adjusted Operating Income	$	1,328	$	249	$	171	$	1	$	1,749

	Retail Pharmacy
	USA		International		Pharmaceutical  Wholesale		Eliminations  and Unallocated  Items			Consolidated
Nine Months Ended May 31, 2016
Operating Income										$	4,861
Acquisition-related amortization											282
LIFO provision											207
Cost transformation											191
Acquisition-related costs											82
Asset impairment											30
Adjusted Operating Income	$	4,257	$	908	$	500	$	(12	)	$	5,653

Nine Months Ended May 31, 2015
Operating Income										$	3,832
Increase in fair market value of AmerisourceBergen warrants											(123	)
Acquisition-related amortization											402
LIFO provision											176
Cost transformation											160
Acquisition-related costs											87
Asset impairment											110
Store closures and other optimization costs											51
Loss on sale of business											12
Adjusted Operating Income	$	4,044	$	374	$	292	$	(3	)	$	4,707